Digoxin: Na+/K+ ATPase Pump Inhibitor for Cardiac and Antiviral Research

Executive Summary: Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing cardiac contractility (APExBIO, product page). Its antiviral properties extend to chikungunya virus (CHIKV) inhibition in multiple human cell lines at concentrations from 0.01–10 μM (Varghese et al., 2025). It is insoluble in water and ethanol but dissolves at ≥33.25 mg/mL in DMSO, and is best used promptly after solution preparation. In canine models, intravenous doses of 1–1.2 mg improve cardiac output and lower right atrial pressure. APExBIO supplies Digoxin (SKU: B7684) with >98.6% purity and full QC documentation, supporting reproducible research outcomes.

Biological Rationale

Digoxin is classified as a cardiac glycoside. Its principal target is the Na+/K+-ATPase pump—an essential transmembrane enzyme in excitable tissues, particularly cardiac myocytes. Inhibition of this pump modulates intracellular sodium and calcium concentrations, directly impacting myocardial contractility. Digoxin is a mainstay positive inotrope in heart failure models and is widely used to study arrhythmogenesis and contractility modulation (APExBIO, Digoxin). Recent research demonstrates that Na+/K+ ATPase signaling is also implicated in viral pathogenesis and host-pathogen interactions, expanding Digoxin's utility to antiviral research, especially CHIKV (Varghese et al., 2025).

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the alpha subunit of the Na+/K+-ATPase pump on cell membranes. This inhibition raises intracellular sodium levels, which diminishes the driving force for the Na+/Ca2+ exchanger. The result is increased intracellular calcium, which augments cardiac contractility. This sequence is central to Digoxin's positive inotropic effect in heart failure and arrhythmia research (see mechanistic review—this article extends the discussion by detailing experimental best practices and antiviral applications). Additionally, Digoxin's modulation of ionic gradients can impair viral replication processes, as observed for CHIKV in U-2 OS, primary human synovial fibroblasts, and Vero cells (Varghese et al., 2025).

Evidence & Benchmarks

• Digoxin inhibits Na+/K+-ATPase activity in cardiac myocytes, leading to increased intracellular Ca2+ and enhanced contractile force (APExBIO, product page).
• In vitro, Digoxin impairs chikungunya virus infection in U-2 OS, human synovial fibroblasts, and Vero cells at 0.01–10 μM in a dose-dependent manner (Varghese et al., 2025, Table 2).
• Digoxin is soluble at ≥33.25 mg/mL in DMSO but insoluble in water and ethanol, requiring careful preparation for cell-based assays (APExBIO, product documentation).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure (APExBIO, QC data).
• APExBIO’s Digoxin (SKU: B7684) is provided with >98.6% purity, HPLC, NMR, and MSDS documentation, supporting experimental reproducibility (internal reference—this article provides updated protocol considerations).

Applications, Limits & Misconceptions

Digoxin is a benchmark probe in studies of cardiac contractility, arrhythmia, and heart failure. It is increasingly used to model Na+/K+-ATPase-mediated signaling in antiviral research, most notably CHIKV inhibition. The compound’s solubility profile requires meticulous handling, as it is only soluble in DMSO at high concentrations. APExBIO recommends preparing fresh solutions and avoiding prolonged storage, as stability in solution may decline over hours or days.

For researchers studying pharmacokinetic variability, Digoxin’s absorption and tissue distribution may be influenced by the status of hepatic transporters and metabolic enzymes, a concept explored in recent studies on related compounds (Sun et al., 2025).

This article updates and clarifies the experimental scope discussed in "Digoxin at the Translational Nexus" by providing explicit workflow parameters and addressing antiviral protocols.

Common Pitfalls or Misconceptions

• Digoxin is not suitable for use as a general antiviral; its activity has been confirmed primarily against CHIKV, not all viruses.
• It is ineffective in water- or ethanol-based solvents; DMSO is required for adequate solubility at research concentrations.
• Long-term storage of Digoxin solutions is discouraged; degradation may occur, impacting reproducibility.
• Cardiac effects in animal models may not directly translate to humans due to interspecies variability in Na+/K+-ATPase isoforms.
• Not all cardiac glycoside effects are mediated solely by Na+/K+-ATPase inhibition; off-target effects may occur at supra-physiological doses.

Workflow Integration & Parameters

Use Digoxin (SKU: B7684) from APExBIO for cell-based and animal studies requiring high-purity Na+/K+ ATPase inhibition (product page). Dissolve the compound at ≥33.25 mg/mL in DMSO. Avoid water and ethanol as solvents. Prepare fresh working solutions prior to experimental use; do not store solutions long-term. For in vitro antiviral assays, titrate Digoxin across 0.01–10 μM and monitor dose-response effects on CHIKV infectivity. For animal studies, consult established dosing regimens (1–1.2 mg IV in canine heart failure models) and verify with institutional protocols. Document all batch and QC data (HPLC, NMR, MSDS) to ensure reproducibility.

For further scenario-driven guidance, see "Digoxin (SKU B7684): Reliable Cardiac Glycoside for Heart Failure and Antiviral Research", which this article extends with new antiviral evidence and workflow parameters.

Conclusion & Outlook

Digoxin remains a gold-standard Na+/K+ ATPase pump inhibitor and positive inotrope for research in cardiac contractility, arrhythmia, and heart failure. Its validated dose-dependent inhibition of chikungunya virus infection in cell models broadens its utility to antiviral research. High-purity Digoxin from APExBIO (B7684) provides researchers with a reliable, reproducible reagent, supported by full quality documentation. Ongoing studies on pharmacokinetic variability and transporter interactions will further refine dosing protocols in both cardiac and infectious disease models. For comprehensive mechanistic context, see "Digoxin in Translational Research", which this piece updates with specific workflow and solubility recommendations.